Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Total Therapy 8: Elotuzumab and VRD in Multiple Myeloma
NCT03168100Phase 2Withdrawn
- Sponsor
- University of Arkansas
- Start
- Oct 2017
- Primary completion
- Jan 2019
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of elotuzumab in multiple myeloma (MM), sponsored by University of Arkansas. Planned start Oct 2017; status: withdrawn.
02
Drugs
elotuzumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03168100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03168100.